Maze Therapeutics
MAZE
26.25
-0.18
-0.68%
Maze Therapeutics
US · MAZE
#2998 by market cap
Listed 2025
26.25
-0.18
-0.68%
Live - 5344 symbols - heartbeat 207s ago
· 2026-10-08 04:44
Pre-market
26.25
0.00%
After-hours
26.25
0.00%
- Market cap
- 1.46B
- P/E (TTM)i
- -10.91
- P/Bi
- 3.22
- EPSi
- -2.66
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on MAZE?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
61.43 +134.0%
Price target rangecurrent 26.25
Low46.00
Avg61.43
High110.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | H.C. Wainwright | -- | BUY | 110.00 |
| 2026-09-23 | Wedbush | -- | BUY | 48.00 |
| 2026-09-23 | Citi | -- | BUY | 50.00 |
| 2026-09-22 | LifeSci Capital | -- | BUY | 57.00 |
| 2026-09-22 | BTIG | -- | BUY | 46.00 |
| 2026-09-22 | Truist Financial | -- | BUY | 64.00 |
| 2026-09-22 | H.C. Wainwright | -- | BUY | 110.00 |
| 2026-09-09 | Wells Fargo | -- | BUY | 55.00 |
| 2026-08-13 | Truist Financial | -- | BUY | 64.00 |
| 2026-08-12 | Wells Fargo | -- | BUY | 55.00 |
| 2026-08-12 | LifeSci Capital | -- | BUY | 57.00 |
| 2026-08-12 | Wedbush | -- | BUY | 48.00 |
| 2026-08-12 | H.C. Wainwright | -- | BUY | 110.00 |
| 2026-08-11 | BTIG | -- | BUY | 46.00 |
| 2026-06-23 | Mizuho Securities | -- | BUY | 97.00 |
| 2026-06-22 | H.C. Wainwright | -- | BUY | 110.00 |
| 2026-05-22 | J.P. Morgan | -- | BUY | 53.00 |
| 2026-05-20 | H.C. Wainwright | -- | BUY | 110.00 |
| 2026-05-16 | LifeSci Capital | -- | BUY | 57.00 |
| 2026-05-14 | Truist Financial | -- | BUY | -- |
| 2026-05-13 | Wells Fargo | -- | BUY | 55.00 |
| 2026-05-13 | LifeSci Capital | -- | BUY | 57.00 |
| 2026-05-13 | Wedbush | -- | BUY | 48.00 |
| 2026-05-13 | H.C. Wainwright | -- | BUY | 110.00 |
| 2026-05-12 | TD Cowen | -- | BUY | -- |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Quote time 2026-10-08 04:44:40 · For reference only, not investment advice and not tailored to your situation.